DMD

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Halladay, J. S.
Right arrow Articles by Sipes, I. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Halladay, J. S.
Right arrow Articles by Sipes, I. G.

Vol. 27, Issue 12, 1456-1465, December 1999

Metabolism and Disposition of [14C]1-Nitronaphthalene in Male Sprague-Dawley Rats

Jason S. Halladay, John-Michael Sauer, and I. Glenn Sipes

Department of Pharmacology and Toxicology and Center for Toxicology, The University of Arizona, Tucson, Arizona

In rats and mice, 1-nitronaphthalene (1-NN) produces both lung and liver toxicity. Even though these toxicities have been reported, the metabolism and disposition of 1-NN have not been elucidated. Therefore, studies were performed to characterize its fate after i.p. and i.v. administration to male Sprague-Dawley rats. After i.p. administration of [14C]1-NN (100 mg/kg; 60 µCi/kg), 84% of the dose was eliminated in the urine and feces by 48 h. At 96 h, 60% of the dose was recovered in the urine, 32% in the feces, and 1% collectively in the tissues, blood, and gastrointestinal contents. The terminal phase rate constant (kterm) of 1-NN was 0.21 h-1, the terminal phase half-life (T1/2,term) was 3.40 h, and the systemic bioavailability was 0.67. When administered i.v. (10 mg/kg; 120 µCi/kg), 85% of the dose was eliminated in the urine and feces by 24 h. At the end of the study (96 h), 56% of the dose was recovered in the urine, 36% in the feces, and 1% collectively in the tissues, blood, and gastrointestinal contents. Interestingly, 88% of the dose was secreted into bile by 8 h. The kterm was 0.94 h-1 and the T1/2,term was 0.77 h. The major urinary metabolite after both routes of administration was N-acetyl-S-(hydroxy-1-nitro-dihydronaphthalene)-L-cysteine. Other urinary metabolites identified include hydroxylated, dihydroxylated, glucuronidated, sulfated, and reduced metabolites, as well as dihydrodiol. The major biliary metabolite was hydroxy-glutathionyl-1-nitro-dihydronaphthalene. These data show that 1-NN undergoes extensive metabolism and enterohepatic recirculation, and the majority of the dose is eliminated in the urine.


Copyright © 1999 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
Am. J. Respir. Cell Mol. Bio.Home page
M. G. Lee, A. M. Wheelock, B. Boland, and C. G. Plopper
Long-Term Ozone Exposure Attenuates 1-Nitronaphthalene-Induced Cytotoxicity in Nasal Mucosa
Am. J. Respir. Cell Mol. Biol., March 1, 2008; 38(3): 300 - 309.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Cell Mol. Bio.Home page
A. M. Wheelock, B. C. Boland, M. Isbell, D. Morin, T. C. Wegesser, C. G. Plopper, and A. R. Buckpitt
In Vivo Effects of Ozone Exposure on Protein Adduct Formation by 1-Nitronaphthalene in Rat Lung
Am. J. Respir. Cell Mol. Biol., August 1, 2005; 33(2): 130 - 137.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
B. Boland, C. Y. Lin, D. Morin, L. Miller, C. Plopper, and A. Buckpitt
Site-Specific Metabolism of Naphthalene and 1-Nitronaphthalene in Dissected Airways of Rhesus Macaques
J. Pharmacol. Exp. Ther., August 1, 2004; 310(2): 546 - 554.
[Abstract] [Full Text] [PDF]


Home page
Toxicol SciHome page
G. L. Baker, M. A. Shultz, M. V. Fanucchi, D. M. Morin, A. R. Buckpitt, and C. G. Plopper
Assessing Gene Expression in Lung Subcompartments Utilizing In Situ RNA Preservation
Toxicol. Sci., January 1, 2004; 77(1): 135 - 141.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
M. A. Shultz, D. Morin, A.-M. Chang, and A. Buckpitt
Metabolic Capabilities of CYP2F2 with Various Pulmonary Toxicants and Its Relative Abundance in Mouse Lung Subcompartments
J. Pharmacol. Exp. Ther., April 13, 2001; 296(2): 510 - 519.
[Abstract] [Full Text]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1999 by the American Society for Pharmacology and Experimental Therapeutics.